Alx Oncology Holdings (ALXO) Interest Expenses (2019 - 2026)

Alx Oncology Holdings (ALXO) has 8 years of Interest Expenses data on file, last reported at $3.8 million in Q1 2026.

• For the quarter ending Q1 2026, Interest Expenses rose 844.83% year-over-year to $3.8 million; the trailing twelve-month figure through Mar 2026 stood at $3.8 million (up 86.03% YoY), and the FY2025 full-year result was $149.7 million, up 2038.62% from the prior year.
• Interest Expenses grew to $3.8 million in Q1 2026, from $626000.0 in the prior quarter.
• In the past five years, Interest Expenses ranged from a high of $3.8 million in Q1 2026 to a low of $2000.0 in Q2 2022.
• A 5-year average of $702764.7 and a median of $408000.0 in 2025 frame the typical range for Interest Expenses.
• Across the five-year window, Interest Expenses sank 99.79% in 2022 and jumped 19450.0% in 2023, its largest moves.
• Tracing ALXO's Interest Expenses over 5 years: stood at $231000.0 in 2022, then soared by 174.46% to $634000.0 in 2023, then rose by 23.19% to $781000.0 in 2024, then declined by 19.85% to $626000.0 in 2025, then surged by 512.78% to $3.8 million in 2026.
• Business Quant data shows ALXO's Interest Expenses at $3.8 million in Q1 2026, $626000.0 in Q4 2025, and $408000.0 in Q3 2025.